ReviewJournal of cellular and molecular medicine2026
Cartilage Extracellular Matrix Homeostasis in Knee Osteoarthritis: Pathomechanisms and Therapeutic Targeting.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Knee osteoarthritis (KOA) is a degenerative joint disease primarily driven by the disruption of homeostasis in the chondrocyte extracellular matrix (CECM). This review systematically examines the central role of CECM homeostasis in KOA pathogenesis and summarizes recent advances in this field. We synthesized contemporary basic and clinical research to analyse the mechanisms underlying CECM homeostatic imbalance. These include biomechanical stress, inflammatory responses, programmed cell death (e.g., apoptosis, pyroptosis, ferroptosis), impaired autophagy, and cellular senescence. We also evaluated intrinsic risk factors and the application of related biomarkers for diagnosis and prognosis. Our analysis identifies multifaceted pathways driving CECM imbalance and highlights promising multi-modal therapeutic strategies. These include novel pharmacological agents (e.g., high-purity chondroitin sulphate, natural active monomers), physical and regenerative therapies (e.g., stem cells, platelet-rich plasma), precision interventions (e.g., gene editing, RNA interference), and tissue engineering approaches (e.g., smart biomaterials, biomimetic scaffolds). The evidence demonstrates that these strategies can effectively modulate CECM metabolism, promote cartilage repair, and slow disease progression. Targeting CECM homeostasis is a core strategy for developing disease-modifying therapies for KOA. Future efforts should focus on interdisciplinary integration, individualized precision medicine, and multi-site synergistic interventions. This review provides a comprehensive foundation for innovating strategies to delay or reverse KOA progression by restoring CECM balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.